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Abstract  
International results have recently questioned the value of 
providing telehealthcare to all COPD patients. Results from 
the Danish TeleCare North trial nuanced the debate by con-
cluding that telehealthcare would most likely only be cost-
effective for patients in a subgroup of severe COPD. Ma-
chine-learning methods have been suggested as a strategy to 
target telehealthcare even better than clinical subgroups. 
Data from the TeleCare North trial was used to fit classifica-
tion models in order to explore this feasibility. Three models 
were applied: a simple decision tree, logistic regression and 
a linear support vector machine. Results indicate that classi-
fication methods can be used to predict patient-level cost-
effectiveness with a relatively high precision. With these 
methods, it is feasible to target telehealthcare even better in 
order to maximize survival and health-related quality of life 
while not overusing scarce health resources as argued by 
health economists and clinical advocates of rational medi-
cine. 
Keywords:   
Pattern Recognition, Automated/classification; Cost-Benefit 
Analysis, Telemedicine; Pulmonary Disease, Chronic Ob-
structive, Denmark. 
Introduction   
Chronic obstructive pulmonary disease (COPD) is a preva-
lent disease [1,2]. The World Health Organization projects 
that 64 million people have COPD worldwide, attributing to 
more than 3 million deaths annually [3]. COPD is a major 
health problem in the European Union with a member state 
COPD prevalence between 4-10% [4]. The Danish Lung As-
sociation estimates that 430,000 Danish citizens have COPD 
[5] with a scientific study setting the prevalence to 9% [6]. 
According to an analysis of the disease burden in Denmark, 
around 3,300 Danish citizens die due to COPD each year 
(6% of total number of deaths) [7] and 2,500 die each year of 
causes related to COPD [8].  
 
Systematic reviews and a recent large-scale randomized trial 
have shown some effect of telehealthcare on health outcomes 
[9–11]. However, due to fiscal pressure in healthcare sectors, 
effective interventions might still not receive public funding, 
if there is not a reasonable relationship between health out-
comes and associated costs [12]. Although several pilot trials 
have suggested that telehealthcare could be cost-effective or 
cost-saving for COPD patients [13–17], recent larger-scale 
studies have found it hard to replicate similar results, sug-
gesting that it might not be cost-effective to scale up tele-
healthcare solutions to all COPD patients assuming that 
“one-solution fit all” [18–21]. 
 
However, there is little knowledge on the implications of 
patient heterogeneity, i.e. that some patient groups might for 
some reason be more or less cost-effective than others. Re-
cent results from the Danish TeleCare North trial is one of 
the first studies to indicate that, although telehealthcare is not 
cost-effective for all COPD patients (21), it might – on aver-
age - be highly cost-effective for patients in the severe COPD 
subgroup [22].  
 
But at the same time, there is a growing demand for targeting 
telehealthcare even better than by clinical subgroups in order 
to identify the contexts and characteristics of ideal individual 
patients that should receive telehealthcare, i.e. enabling as-
sessment that answers under which circumstances tele-
healthcare would be most likely to be cost-effective [23–25]. 
Machine-learning methods used to predict outcomes for indi-
vidual patients eligible for telehealthcare has recently been 
suggested as one way forward [26]. 
 
The aim of this project is to investigate if it is possible to use 
predictive algorithms to help stratify telehealthcare for 
COPD patients in a way that maximizes the patient-level 
cost-effectiveness ratio. 
Materials and Methods  
Data 
The study design, data collection procedure [27] as well as 
the results of TeleCare North has been been published else-
where [21,22]. In addition to usual care, patients in the inter-
vention group received a set of telehealthcare equipment, 
disease-specific education and were monitored by a munici-
pality-based healthcare team. The control group received 
usual care. 1,225 patients were included with 578 patients 
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receiving telehealthcare and 647 usual care. The duration of 
the study was 12 months.  
For the purposes of this study, the variables collected as part 
of the study is of particular interest and can be divided into 
the cost-effectiveness ratio to be predicted and a set of fea-
tures used to predict this outcome. 
Outcome 
The primary outcome is the total costs per quality-adjusted 
life year (QALY) gained at the individual level, which repre-
sent an individualized cost-effectiveness ratio.  
A QALY is a composite measure of survival and health-
related quality-of-life (HRQoL) [28]. Information on mortali-
ty was taken from the Danish Register of Causes of Death 
[29]. HRQoL stemmed from generic EQ-5D-3L question-
naires distributed to patients at baseline and 12-months fol-
low-up. The EQ-5D scores HRQoL on a scale from 0-1, 
where “1” indicates perfect HRQoL and “0” meaning dead. 
Negative scores are possible indicating health states consid-
ered worse than death [30]. QALYs were calculated by linear 
interpolation of EQ5D-3L scores with Danish societal 
weights [31,32]. 
Total costs included intervention costs, healthcare costs 
(hospital-, medicine-, and primary sector costs), and social 
sector costs (cost to practical help and care at home, home-
based nursing care, and rehabilitation). Within-trial 
healthcare costs were all collected from national registers by 
applying patients’ unique social security number. Hospital 
contacts were collected from the Danish National Patient 
Register [33]; contacts between patients and the primary care 
sector from the National Health Insurance Service Register 
[34]; and medication use was taken from The Danish Regis-
ter of Medicinal Product Statistics [35]. Social sector costs 
was estimated from electronic care systems in each of the 10 
included municipalities. Intervention costs were assessed 
from prices paid during the TeleCare North implementation 
and included costs of hardware, installation, maintenance and 
support as well as training costs, monitoring costs, and pro-
ject management costs. All costs were reported in 2014 pric-
es and were obtained in Danish kroner (DKK) and thereafter 
exchanged to € using the average 2014 exchange rate 
(1€=7.4547 DKK). 
Features 
Different baseline features were collected as part of the trial. 
All features originated from a combination of questionnaires, 
physical measurements conducted by general practitioners 
and from national registers. Three baseline HRQoL summary 
scores (baseline EQ-5D, PCS and MCS scores) was available 
from two generic questionnaires distributed to all patients: 
the EQ-5D-3L [30] and the SF-36 [36]. Six physiological 
parameters was measured by the patients’ general practition-
er and consisted of systolic- and diastolic blood pressure, 
pulse, body mass index (BMI), spirometry measures (per-
centage of expected forced expiratory volume in one second 
(FEV1 (%)), percentage of expected forced vital capacity 
(FVC (%)). Six socio-demographics (marital status, highest 
education, duration of COPD, job status, number of persons 
in household and smoking status) and the presence of five 
comorbidities (diabetes, musculoskeletal disease, cancer, 
mental illness and heart disease) was ascertained from ques-
tionnaires that were filled out by patients. Age and gender 
was identified from the patients’ social security number and 
their residing municipality was collected from the Danish 
Civil Registration System [37]. Nine features associated with 
the historical activity for the included patients was incorpo-
rated to account for organizational differences and variation 
in visitation practices. Therefore, the number and duration of 
hospital admissions and the number of outpatient visits one 
year prior to randomization was included as were the costs 
associated with these contacts. Costs due to medicine, prima-
ry care and practical help and care at home, home-based 
nursing care, and rehabilitation was also collected for the one 
year leading up to the evaluation period. All features was 
collected from the same national registers as described 
above. 
 
In total, the dataset consist of 32 features. In addition, six 
predictors were derived from other features: In the original 
cost-effectiveness analysis, three characteristics were im-
portant in distinguishing between subgroups that were more 
cost-effective than others [22].The cost-effectiveness of tele-
healthcare depended on COPD severity group that can be 
calculated from FEV1(%) [38]. Furthermore, existing social 
sector costs was a driver of cost-effectiveness; as were base-
line cost (accumulated costs one year prior to evaluation). 
Both variables were calculated from the individual baseline 
cost-categories that were collected as part of the trial. Three 
other features were generated that indicate whether a patient 
suffer from hypertension, multimorbidities or tachycardia and 
they were calculated from blood pressure, individual 
comorbidities and pulse, respectively. These were included 
because of their clinical meaningfulness. 
Missing data 
Of the 1,225 patients originally included in the TeleCare 
North trial, complete data for both total costs (i.e. all cost 
categories), baseline EQ-5D score and EQ-5D score at fol-
low-up were available for 728 patients (59%; 302 in tele-
healthcare group; 426 in control group). Missing data for the 
EQ-5D summary score were present for 8% of the partici-
pants at baseline (48 in the telehealthcare group; 53 in the 
control group). Due to non-response or to incomplete regis-
tration of EQ-5D questionnaire items, 27% had missing data 
on the EQ-5D summary score at follow-up (199 in the tele-
healthcare group; 133 in the control group). Two municipali-
ties where unable to extract rehabilitation costs (79 in the 
telehealthcare group; 73 in the control group).  
 
Only the 302 participants with complete outcome data in the 
telehealthcare group were included in this analysis. 
 
Missing data in any features from those 302 participants were 
replaced by multiple imputation. Missing feature values were 
assumed missing at random (MAR) at replaced with the mi 
impute chained command in STATA12.1 and 30 complete 
datasets were created an averaged to one value per missing. 
Continuous variables were imputed by predictive mean 
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matching and categorical variables by multinomial logistic or 
logistic regression. Imputation models included predictors for 
the outcomes at both time points and predictors for missing 
observations in the individual variables. The imputation 
models were estimated separately by treatment group and 
included the clustering variable and the measures of disease 
status, presence of comorbidities and sociodemographic vari-
ables described previously.  
 
The characteristics of the included patients are presented in 
Table 1.  
 
Table 1- Baseline characteristics of the sample (n=302)  
 
Age (years) 69.57 (8.87) 
Men (%) 50.99 (n=154) 
Marital status  
 Married/in a relationship 66.56 (n=201) 
 Single 17.55 (n=53) 
 Widow/widower 15.89 (n=48) 
Smoking status  
 Non-smokers 65.89 (n=199) 
 Smokers 34.11 (n=103) 
Highest education  
 Elementary school 46.03 (n=139) 
 Secondary school 4.30 (n=13) 
 Vocational education 34.77 (n=105) 
 Short tertiary school (2-3 
years) 
7.95 (n=24) 
 Bachelor or equivalent (3-5 
years) 
6.95 (n=21) 
 Master or equivalent (>5 
years) 
0.00 (n=0) 
Job status  
 Full-time 3.64 (n=11) 
 Part-time 7.28 (n=22) 
 None 89.07 (n=269) 
Blood pressure, diastolic 76.64 (10.51) 
Blood pressure, systolic 130.62 (16.97) 
Pulse 79.12 (13.31) 
BMI 26.22 (5.01) 
Duration of COPD (years) 7.97 (6.10) 
FEV1 (%) 47.57 (16.29) 
FVC (%) 70.85 (16.94) 
Comorbidities  
 Diabetes 10.69 (n=32) 
 Heart disease 32.12 (n=97) 
 Mental health problem 3.31 (n=10) 
 Musculoskeletal disease 25.83 (n=78) 
 Cancer 5.63 (n=17) 
Baseline total cost (€) 4,863.37 (7,874.23) 
Baseline HRQoL  
 EQ-5D score 0.727 (0.20) 
 PCS (SF-36 physical score) 38.30 (8.68) 
 MCS (SF-36 mental score) 48.98 (10.97) 
Data are mean (SD) or proportion (number of patients) 
COPD: Chronic obstructive pulmonary disease; FEV1(%): forced expiratory 
volume in one second of predicted normal; FVC(%): forced vital capacity 
 
Model and features 
To investigate some basic methods of machine-learning, a 
relative naïve approach was chosen for this study. The pre-
diction of cost-effectiveness was addressed as a simple pat-
tern classification problem to test different methods.  
 
First, all 38 features regardless of multicollinearity were used 
in subsequent analyses. 
 
Second, the individualized cost-effectiveness ratio was cate-
gorized into two groups (Class 1: Total cost/QALY≤ €5,000;  
Class 2: Total cost/QALY>€5,000). This was done due to 
simplicity and because the cost-effectiveness ratio was highly 
skewed even after normalization. The boundary was explora-
tively chosen based on the distribution of the individualized 
cost-effectiveness ratio.  
 
Third, MATLAB Release 2017a was used to train and evalu-
ate all 38 predictors using a five-fold cross-validation. A 
simple decision tree, logistic regression and linear support 
vector machines were fitted to the data. 
Evaluation 
All models were evaluated based on accuracy and the area 
under the receiver operating characteristics curve (AUC). 
Accuracy is the proportion of correct predictions made for 
the two cost-effectiveness categories among the total number 
of observations. The AUC curve quantifies the overall ability 
of the classification model to discriminate between observa-
tions that have a total cost/QALY ≤ €5,000 or >€5,000 across 
classification thresholds. A model with no better precision 
than chance has an AUC of 0.5. 
Results  
Table 2 presents model performance for each of the three 
models that were fitted. The linear SVM performed best with 
an accuracy of 79.1% and an area under the curve of 0.89. 
The classification model was therefore able to classify 79% 
of the observations into the correct cost-effectiveness catego-
ries with a relatively high ability to distinguish which obser-
vations should be predicted to have an individualized cost-
effectiveness larger or smaller than €5,000 across classifica-
tion levels.  
 
Moreover, all three models had relatively high performance 
(accuracy between 76.7-79.1% and area under the curves 
between 0.81-0.89). 
 
Table 2- Performance evaluation of the included models  
 
 Accuracy (%) AUC 
Simple tree 76.7 0.81 
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Logistic regression 77.4 0.84 
Linear SVM 79.1 0.89 
AUC: Area under the curve; SVM: Support vector machine 
 
Figure 1 and Figure 2 presents the receiver operation charac-
teristics of both classes (Class 1: Total cost/QALY≤ €5,000; 
Class 2: Total cost/QALY>€5,000) for the best performing 
classification model (linear SVM). 
 
Figure 1- Receiver operation characteristics based on a lin-
ear support vector machine (Class 1) 
 
 
 
Figure 2- Receiver operation characteristics based on a lin-
ear support vector machine (Class 2) 
 
Discussion 
The best performing model was the linear SVM, but all three 
compared models had relatively high accuracy (from 76.7-
79.1) and large area under the ROC-curves (from 0.81-0.89). 
This seems to suggest that machine-learning methods can be 
used to predict the individualized cost-effectiveness of tele-
health to COPD patients with a relatively high precision. 
Strength/weaknesses 
This study applied data from a large clinical trial that rigor-
ously collected patient-level data on both health outcomes, 
socio-demographics and resource patterns across all relevant 
stakeholders involved in managing COPD patients. All cost 
data are based on unambiguous register-data complete elimi-
nating any self-report biases.  
   
A limitation is that no feature selection was conducted prior 
to model training. Using 38 features to predict a two-
category outcome resulting in a relatively high precision 
might be due to overfitting of the data, which means that the 
models accurately classifies the training data, but would per-
form poorly on future data. A five-fold cross validation was 
used to counter some of the problems of overfitting the data, 
but in general, much fewer features could make the same 
classification. From the original cost-effectiveness analysis, 
it is known that especially baseline HRQoL and total base-
line costs (the sum of costs accumulated from all cost-
categories 12 months prior to evaluation start) had a major 
impact on the cost-effectiveness estimate [21]. For this rea-
son baseline EQ-5D is required as a variable in any models 
estimating cost-effectiveness in health economic research 
[39]. 
 
Another limitation is that no techniques for dealing with out-
liers were applied. It could rightfully be stated that very large 
outliers are attributed to patients having other serious disease 
alongside COPD. However, models did account for major 
comorbidities and baseline total costs. And health economists 
will insist on asking what threshold levels constitutes an out-
lier given smooth cost-effectiveness distributions and argue 
that outliers are crucial for estimating impact on healthcare 
budgets, which is why mean values instead of medians are 
always reported [40,41]. 
 
Finally, large proportions of missing data can be a particular 
problem in machine-learning. In clinical trials, good practice 
implies handling missing data with multiple imputation 
[42,43]; but this procedure could artificially boost the per-
formance of prediction models, since multiple imputation 
entails using other variables to predict missing values. This 
study therefore sought to minimize the missing data chal-
lenge by focusing on the telehealthcare group with complete 
cost-effectiveness ratio. But these participants still had miss-
ing data on especially socio-demographics and physical 
measurements used to predict cost-effectiveness. 
Comparison with other research 
While some studies have applied machine-learning tech-
niques in medicine to predict outcomes related to health eco-
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nomic evaluation, i.e. mortality in heart disease [44], HRQoL 
in COPD [45] and even the cost of treatment in liver disease 
[46]; no other studies have been found that sought directly to 
predict the cost-effectiveness ratio of health technologies.  
 
The study published by Stausholm and colleagues  [44] come 
closest to the design of this study. It applied data from the 
TeleCare North trial to predict increasing or decreasing 
HRQoL and healthcare sector costs for 553 COPD patients 
receiving both telehealthcare and usual care. The design en-
tailed application of four different logistic regression models 
with 39 features, which were evaluated by accuracy and root 
mean square error (RMSE). Accuracy of models ranged from 
61-65% for models predicting HRQoL and 74-75% for mod-
els predicting healthcare sector costs, while the RMSE was 
5.265 scores for HRQoL and $5430 for healthcare costs. The 
study concluded that predictive analytics could be used to 
stratify COPD patients for telehealthcare. This current study 
has a slightly higher accuracy (76.7-79.1%) with roughly the 
same number of features. However, this study applied a dif-
ferent HRQoL summary score (the EQ-5D as opposed to SF-
36 in Stausholm) and accounted for a much broader cost-
perspective. Especially costs in municipalities (due to daily 
practical help and home nursing care) led to larger proportion 
of COPD patients to have very large costs, that were in part 
accounted for by including a feature for having resource use 
in municipalities prior to data collection.  
Implications 
Based on the cost-effectiveness results from the TeleCare 
North trial, the Danish Government decided to fund tele-
healthcare to the subgroup of patients with severe COPD 
throughout Denmark [47]. Although, this subgroup was like-
ly to be cost-effective on average, there is both a scientific 
and practical need to select COPD patients from an even 
more limited set of potential candidates for telehealthcare 
[26]. This would result in a quicker and less expensive im-
plementation of telehealthcare that would facilitate better 
health outcomes while also reducing overall health- and so-
cial care costs. 
 
Machine-learning methods already has an established role in 
healthcare and biomedicine [48] in areas such as disease dis-
covery, e.g. [49] and diagnosis [50]. Results from this study 
seems to indicate that it would be possible to predict individ-
ual cost-effectiveness of telehealthcare for future patients. 
This would enable more personalized COPD management, 
i.e. a COPD management strategy that are based on individu-
al data paired with a predictive toolbox that evaluates which 
combinations of individuals and technologies, that are eligi-
ble for receiving public funding. 
Future research 
More studies on the type of models used to predict cost-
effectiveness should be conducted. The individualized cost-
effectiveness ratio is a very left-skewed ratio-scaled variable 
ranging, in principle, from -∞ to +∞, but with mostly positive 
values. This study applied a pattern recognition strategy by 
dividing cost-effectiveness into two categories, but models 
that are used to predict the continuous cost-effectiveness ra-
tio or even more cost-effectiveness categories could have 
been applied instead.  
 
New predictive models might also need to be developed and 
incorporated into existing software that can account for the 
clustered nature of health- and cost data: due to variation in 
practice, it is plausible that mortality, health-related quality 
of life and costs are more similar within e.g. geographical 
areas or the patients’ organizational affiliation than across 
these areas. Treating this information merely as fixed varia-
bles in modelling outcomes can lead to biased model coeffi-
cients and –uncertainty [51,52].  
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